Browse by author
Lookup NU author(s): Dr Daniel Williamson, Dr Ed Schwalbe, Professor Simon BaileyORCiD, Professor Steven CliffordORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2023 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society. The childhood brain tumour medulloblastoma is typically classified into multiple discrete molecular subgroups with characteristic DNA methylation and expression patterns. Several of these subgroups are used as, or proposed to be, an effective basis for treatment stratification. Here, we highlight the close connection between the findings described in a recent series of studies which, together, strongly imply a continuous association between survival outcome, the transcriptional profile of a Group3/Group4 (i.e. non-WNT/non-SHH) medulloblastoma and the specific point during early foetal cerebellar development at which initial pathogenic disruption took place. This has important implications for future efforts to model the disease by incorporating driving molecular features into their specific developmental context. This further suggests that instead of relying upon discrete DNA methylation subgroups, using expression biomarkers as the basis of a continuous risk predictor may produce a more effective risk stratification of patients with Group3/Group4 medulloblastoma.
Author(s): Williamson D, Schwalbe EC, Bailey S, Clifford SC
Publication type: Review
Publication status: Published
Journal: Neuropathology and Applied Neurobiology
Year: 2023
Volume: 49
Issue: 3
Print publication date: 01/06/2023
Online publication date: 06/04/2023
Acceptance date: 30/03/2023
ISSN (print): 0305-1846
ISSN (electronic): 1365-2990
Publisher: Wiley-Blackwell Publishing Ltd
URL: https://doi.org/10.1111/nan.12903
DOI: 10.1111/nan.12903
PubMed id: 37021628
